Product Information
DEXTROMETHORPHAN ER 30 MG/5 ML is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.0664 per ML under NDC 45802043321. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on May 25, 2012.
Strength
30 mg/5mL
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802043321
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DEXTROMETHORPHAN HYDROBROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA091135FDA Approved
5/25/2012
On Market Since
9/10/2012
Pharmacological Classes
Price Statistics
The NADAC for DEXTROMETHORPHAN ER 30 MG/5 ML has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 19.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0664 per ML |
|---|---|
| All-time high | $0.0708 (Jun 14, 2023) |
| All-time low | $0.0545 (Aug 23, 2017) |
| 52-week high | $0.0682 |
| 52-week low | $0.0649 |
| Median price | $0.0575 |
| Average price | $0.0597 |
| Largest weekly change | -12.2% (Jun 21, 2023) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 21% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dextromethorphan polistirex market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sigma-1 Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEXTROMETHORPHAN ER 30 MG/5 ML?
The current National Average Drug Acquisition Cost (NADAC) for DEXTROMETHORPHAN ER 30 MG/5 ML, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.0664 per ML (NDC 45802043321), effective Sep 30, 2026.
How has the price of DEXTROMETHORPHAN ER 30 MG/5 ML changed over time?
Over the history we have for it, the NADAC for DEXTROMETHORPHAN ER 30 MG/5 ML has risen 19.1%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DEXTROMETHORPHAN ER 30 MG/5 ML?
Since Nov 28, 2013, the NADAC for DEXTROMETHORPHAN ER 30 MG/5 ML has ranged from a low of $0.0545 (Aug 23, 2017) to a high of $0.0708 (Jun 14, 2023), with a median of $0.0575 per ML.
Are there cheaper alternatives to DEXTROMETHORPHAN ER 30 MG/5 ML?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, COUGH DM ER 30 MG/5 ML SUSP, is $0.0525 per ML — about 21% below DEXTROMETHORPHAN ER 30 MG/5 ML.
Who manufactures DEXTROMETHORPHAN ER 30 MG/5 ML?
DEXTROMETHORPHAN ER 30 MG/5 ML (NDC 45802043321) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.